![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
Stroke prevention |
Prostate Cancer |
Free Subscription
2 BJU Int |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Prostate Cancer is free of charge.
How and when should radiologists report T-staging on MRI in patients with
prostate cancer?
BJU Int. 2022 Jun 13. doi: 10.1111/bju.15824.
PubMed
Comprehensive review of hydrogel spacers prior to radiation therapy for prostate
cancer.
BJU Int. 2022 Jun 10. doi: 10.1111/bju.15821.
PubMed
Abstract available
Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical
response in castration-sensitive prostate cancer.
Clin Cancer Res. 2022 Jun 13. pii: 704873. doi: 10.1158/1078-0432.CCR-22-0851.
PubMed
Abstract available
Can high b-value 3.0 T biparametric MRI with the Simplified Prostate Image
Reporting and Data System (S-PI-RADS) be used in biopsy-naive men?
Clin Imaging. 2022;88:80-86.
PubMed
Abstract available
Transperineal Prostate Biopsy Is the New Black: What Are the Next Targets?
Eur Urol. 2022;82:3-5.
PubMed
Abstract available
Re: Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional
Sampling.
Eur Urol. 2022;82:143-144.
PubMed
Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical
Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance
Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. Eur
Urol. In pr
Eur Urol. 2022;82:e15-e16.
PubMed
Re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or
Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized
Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP
Consortium.
Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02411.
PubMed
Overall Survival Update for Patients with Metastatic Castration-resistant
Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID
Clinical Trial.
Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02393.
PubMed
Abstract available
Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re:
Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core
Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic
Castration-resi
Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02388.
PubMed
Reply to Yongfeng Lao, Yanan Wang, and Zhilong Dong's Letter to the Editor re:
Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or
Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized
Prostate Cancer: An
Eur Urol. 2022 Jun 7. pii: S0302-2838(22)02410.
PubMed
Reply to Francesco Montorsi, Armando Stabile, Elio Mazzone, Giorgio Gandaglia,
and Alberto Briganti's Letter to the Editor re: Deepika Reddy, Max Peters, Taimur
T. Shah, et al. Cancer Control Outcomes Following Focal Therapy Using
High-intensity Focus
Eur Urol. 2022 Jun 8. pii: S0302-2838(22)02412.
PubMed
(18)F-PSMA-11 Versus (68)Ga-PSMA-11 Positron Emission Tomography/Computed
Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A
Prospective Double-blind Randomised Cross-over Trial.
Eur Urol. 2022 Jun 8. pii: S0302-2838(22)02383.
PubMed
Abstract available
Proteome profiling of enzalutamide-resistant cell lines and serum analysis
identified ALCAM as marker of resistance in castration-resistant prostate cancer.
Int J Cancer. 2022 Jun 11. doi: 10.1002/ijc.34159.
PubMed
Abstract available
Combination of biparametric magnetic resonance imaging with prostate-specific
antigen density to stratify the risk of significant prostate cancer: Initial
biopsy and long-term follow-up results.
Int J Urol. 2022 Jun 13. doi: 10.1111/iju.14948.
PubMed
Abstract available
Deep Learning Reconstruction Enables Highly Accelerated Biparametric MR Imaging
of the Prostate.
J Magn Reson Imaging. 2021 Dec 7. doi: 10.1002/jmri.28024.
PubMed
Abstract available
The Oncology Care Model and Adherence to Oral Cancer Drugs: A
Difference-in-Differences Analysis.
J Natl Cancer Inst. 2022;114:871-877.
PubMed
Abstract available
The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation
on (68)Ga-PSMA-11 PET/CT in Primary Prostate Cancer Patients.
J Nucl Med. 2022 Jun 9. pii: jnumed.122.264101. doi: 10.2967/jnumed.122.264101.
PubMed
Abstract available
Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in
Metastatic Prostate Cancer: We have the answers.
J Nucl Med. 2022 Jun 9. pii: jnumed.122.264394. doi: 10.2967/jnumed.122.264394.
PubMed
Robot-Assisted Radical Prostatectomy Using the KangDuo Surgical Robot-01 System:
A Prospective, Single-Center, Single-Arm Clinical Study.
J Urol. 2022;208:119-127.
PubMed
Abstract available
The Effect of Different Types of Prostate Biopsy Techniques on Post-Biopsy
Infectious Complications.
J Urol. 2022;208:109-118.
PubMed
Abstract available
Cabozantinib in combination with atezolizumab in patients with metastatic
castration-resistant prostate cancer: results from an expansion cohort of a
multicentre, open-label, phase 1b trial (COSMIC-021).
Lancet Oncol. 2022 Jun 8. pii: S1470-2045(22)00278.
PubMed
Abstract available
Darolutamide in Metastatic Prostate Cancer.
N Engl J Med. 2022;386:2344.
PubMed
Darolutamide in Metastatic Prostate Cancer.
N Engl J Med. 2022;386:2344.
PubMed
Darolutamide in Metastatic Prostate Cancer. Reply.
N Engl J Med. 2022;386:2345.
PubMed
Dual STAT3 and IL6R inhibition with stattic and tocilizumab decreases migration,
invasion and proliferation of prostate cancer cells by targeting the
IL6/IL6R/STAT3 axis.
Oncol Rep. 2022;48.
PubMed
Abstract available
Lessons learned after one year of COVID-19 from a urologist and radiotherapist
view: A German survey on prostate cancer diagnosis and treatment.
PLoS One. 2022;17:e0269827.
PubMed
Abstract available
Thank you for your interest in scientific medicine.
This policy is made possible thanks to
a media sponsorship by